A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in
participants with metastatic castration-resistant prostate cancer (mCRPC).